Biologically inspired strategies for combating bacterial biofilms

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 699-706

  Blackledge, Meghan S ^a   Worthington, Roberta J ^a   Melander, Christian ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA DEFENSIN 2; CHLORHEXIDINE GLUCONATE; DEOXYRIBONUCLEASE; DORNASE ALFA; MONOCLONAL ANTIBODY; N ACYLHOMOSERINE LACTONE; NUCLEOSIDE DERIVATIVE; POVIDONE IODINE; PROTEIN HISTIDINE KINASE; PROTEINASE K; TOBRAMYCIN; TRICLOSAN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIUM ADHERENCE; BACTERIUM MUTANT; BIOFILM; CELL COMMUNICATION; CYSTIC FIBROSIS; DRUG STRUCTURE; ENZYMATIC DEGRADATION; EXTRACELLULAR MATRIX; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUORUM SENSING; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; HUMANS; QUORUM SENSING; SIGNAL TRANSDUCTION;

EID: 84892957825     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.07.004     Document Type: Review

References (90)

1. Klevens RM, Morrison MA, Nadle J et al.: Invasive methicillin- resistant Staphylococcus aureus infections in the United States. J Am Med Assoc 2007, 298: 1763-1771. (Pubitemid 47598444)
2. Roberts RR, Hota B, Ahmad I et al.: Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009, 49: 1175-1184.
3. Davies D: Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2003, 2: 114-122. (Pubitemid 37361643)
4. Donlan RM: Biofilms: microbial life on surfaces. Emerg Infect Dis 2002, 8: 881-890. (Pubitemid 35000803)
5. Worthington RJ, Blackledge MS, Melander C: Small molecule inhibition of bacterial two-component systems to combat antibiotic resistance and virulence. Future Med Chem 2013, 5(11) http://dx.doi.org/10.4155/FMC.13.58.
6. Yang L, Liu Y, Wu H et al.: Combating biofilms. FEMS Immunol Med Microbiol 2012, 65(2): 146-157.
7. Richards JJ, Melander C: Controlling bacterial biofilms. Chembiochem 2009, 10: 2287-2294.
8. Gaddy JA, Actis LA: Regulation of Acinetobacter baumannii biofilm formation. Future Microbiol 2009, 4: 273-278.
9. Rogers SA, Huigens RW, Cavanagh J, Melander C: Synergistic effects between conventional antibiotics and 2- aminoimidazole-derived antibiofilm agents. Antimicrob Agents Chemother 2010, 54: 2112-2118.
10. Worthington RJ, Richards JJ, Melander C: Small molecule control of bacterial biofilms. Org Biomol Chem 2012, 10: 7457-7474.
11. Camilli A, Bassler BL: Bacterial small-molecule signaling pathways. Science 2006, 311: 1113-1116.
12. Amara N, Mashiach R, Amar D et al.: Covalent inhibition of bacterial quorum sensing. J Am Chem Soc 2009, 131: 10610-10619.
13. Finch RG, Pritchard DI, Bycroft BW, Williams P, Stewart GS: Quorum sensing: a novel target for anti-infective therapy. J Antimicrob Chemother 1998, 42: 569-571. (Pubitemid 28510613)
14. Hentzer M, Wu H, Andersen JB et al.: Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003, 22: 3803-3815. (Pubitemid 36975709)
15. Geske GD, O'neill JC, Blackwell HE: Expanding dialogues: from natural autoinducers to non-natural analogues that modulate quorum sensing in Gram-negative bacteria. Chem Soc Rev 2008, 37: 1432-1447.
16. Geske GD, Wezeman RJ, Siegel AP, Blackwell HE: Small molecule inhibitors of bacterial quorum sensing and biofilm formation. J Am Chem Soc 2005, 127: 12762-12763. (Pubitemid 41339140)
17. Ishida T, Ikeda T, Takiguchi N, Kuroda A, Ohtake H, Kato J: Inhibition of quorum sensing in Pseudomonas aeruginosa by N-acyl cyclopentylamides. Appl Environ Microbiol 2007, 73: 3183-3188. (Pubitemid 46834968)
18. Bottomley MJ, Muraglia E, Bazzo R, Carfi A: Molecular insights into quorum sensing in the human pathogen Pseudomonas aeruginosa from the structure of the virulence regulator LasR bound to its autoinducer. J Biol Chem 2007, 282: 13592-13600. (Pubitemid 47100513)
19. Lyon GJ, Muir TW: Chemical signaling among bacteria and its inhibition. Chem Biol 2003, 10: 1007-1021. (Pubitemid 37496431)
20. Bordi C, De Bentzmann S: Hacking into bacterial biofilms: a new therapeutic challenge. Ann Intensive Care 2011, 1:19.
21. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW: Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 2003, 1: 667-683. (Pubitemid 38855130)
22. Giacometti A, Cirioni O, Gov Y et al.: RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47: 1979-1983. (Pubitemid 36637826)
23. Balaban N, Cirioni O, Giacometti A et al.: Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 2007, 51: 2226-2229. (Pubitemid 46903124)
24. Chan WC, Coyle BJ, Williams P: Virulence regulation and quorum sensing in staphylococcal infections: competitive AgrC antagonists as quorum sensing inhibitors. J Med Chem 2004, 47: 4633-4641. (Pubitemid 39195552)
25. Fowler SA, Stacy DM, Blackwell HE: Design and synthesis of macrocyclic peptomers as mimics of a quorum sensing signal from Staphylococcus aureus. Org Lett 2008, 10: 2329-2332.
26. Tal-Gan Y, Stacy DM, Foegen MK, Koenig DW, Blackwell HE: Highly Potent Inhibitors of Quorum Sensing in Staphylococcus aureus revealed through a systematic synthetic Study of the group-III autoinducing peptide. J Am Chem Soc 2013, 135(21): 7869-7882.
27. Dong YH, Zhang LH: Quorum sensing and quorum-quenching enzymes. J Microbiol 2005, 43 Spec No: 101-109.
28. Dong YH, Xu JL, Li XZ, Zhang LH: AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. Proc Natl Acad Sci USA 2000, 97: 3526-3531.
29. Dong YH, Wang LH, Xu JL, Zhang HB, Zhang XF, Zhang LH: Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature 2001, 411: 813-817.
30. Bijtenhoorn P, Schipper C, Hornung C et al.: BpiB05, a novel metagenome-derived hydrolase acting on N-acylhomoserine lactones. J Biotechnol 2011, 155: 86-94.
31. Hardie KR, Heurlier K: Establishing bacterial communities by 'word of mouth': LuxS and autoinducer 2 in biofilm development. Nat Rev Microbiol 2008, 6: 635-643. (Pubitemid 352006105)
32. Brackman G, Celen S, Baruah K et al.: AI-2 quorum-sensing inhibitors affect the starvation response and reduce virulence in several Vibrio species, most likely by interfering with LuxPQ. Microbiology 2009, 155(Pt 12): 4114-4122.
33. Gutierrez JA, Crowder T, Rinaldo-Matthis A, Ho MC, Almo SC, Schramm VL: Transition state analogs of 50- methylthioadenosine nucleosidase disrupt quorum sensing. Nat Chem Biol 2009, 5: 251-257.
34. Roy V, Meyer MT, Smith JA et al.: AI-2 analogs and antibiotics: a synergistic approach to reduce bacterial biofilms. Appl Microbiol Biotechnol 2013, 97: 2627-2638.
35. Ryjenkov DA, Tarutina M, Moskvin OV, Gomelsky M: Cyclic diguanylate is a ubiquitous signaling molecule in bacteria: insights into biochemistry of the GGDEF protein domain. J Bacteriol 2005, 187: 1792-1798. (Pubitemid 40289381)
36. Tamayo R, Pratt JT, Camilli A: Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annu Rev Microbiol 2007, 61: 131-148. (Pubitemid 350058203)
37. Karaolis DK, Rashid MH, Chythanya R, Luo W, Hyodo M, Hayakawa Y: c-di-GMP (30-50-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation. Antimicrob Agents Chemother 2005, 49: 1029-1038. (Pubitemid 40327720)
38. Brouillette E, Hyodo M, Hayakawa Y, Karaolis DK, Malouin F: 30,50- Cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob Agents Chemother 2005, 49: 3109-3113. (Pubitemid 41060547)
39. Kline T, Jackson SR, Deng W, Verlinde CL, Miller SI: Design and synthesis of bis-carbamate analogs of cyclic bis-(30-50)- diguanylic acid (c-di-GMP) and the acyclic dimer PGPG. Nucleosides Nucleotides Nucleic Acids 2008, 27: 1282-1300.
40. Ching SM, Tan WJ, Chua KL, Lam Y: Synthesis of cyclic di- nucleotidic acids as potential inhibitors targeting diguanylate cyclase. Bioorg Med Chem 2010, 18: 6657-6665.
41. Kalia D, Merey G, Nakayama S et al.: Nucleotide, c-di-GMP, c-di- AMP, cGMP, cAMP, (p)ppGpp signaling in bacteria and implications in pathogenesis. Chem Soc Rev 2013, 42: 305-341.
42. Tomaras AP, Flagler MJ, Dorsey CW, Gaddy JA, Actis LA: Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology. Microbiology 2008, 154: 3398-3409.
43. Kenney LJ: Structure/function relationships in OmpR and other winged-helix transcription factors. Curr Opin Microbiol 2002, 5: 135-141. (Pubitemid 34289919)
44. Gooderham WJ, Hancock RE: Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev 2009, 33: 279-294.
45. Gotoh Y, Eguchi Y, Watanabe T, Okamoto S, Doi A, Utsumi R: Two-component signal transduction as potential drug targets in pathogenic bacteria. Curr Opin Microbiol 2010, 13: 232-239.
46. Schaller GE, Shiu SH, Armitage JP: Two-component systems and their co-option for eukaryotic signal transduction. Curr Biol 2011, 21:R320-R330.
47. Bourret RB, Hess JF, Simon MI: Conserved aspartate residues and phosphorylation in signal transduction by the chemotaxis protein chey. Proc Natl Acad Sci USA 1990, 87: 41-45.
48. Stock JB, Stock AM, Mottonen JM: Signal transduction in bacteria. Nature 1990, 344: 395-400.
49. Martinezhackert E, Stock AM: Structural relationships in the OmpR family of winged-helix transcription factors. J Mol Biol 1997, 269: 301-312. (Pubitemid 27267754)
50. Barbieri CM, Mack TR, Robinson VL, Miller MT, Stock AM: Regulation of response regulator autophosphorylation through interdomain contacts. J Biol Chem 2010, 285: 32325-32335.
51. Eguchi Y, Kubo N, Matsunaga H, Igarashi M, Utsumi R: Development of an antivirulence drug against Streptococcus mutans: repression of biofilm formation, acid tolerance, and competence by a histidine kinase inhibitor, walkmycin C. Antimicrob Agents Chemother 2011, 55: 1475-1484.
52. Okada A, Igarashi M, Okajima T et al.: Walkmycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth. J Antibiot (Tokyo) 2010, 63: 89-94.
53. Qi F, Merritt J, Lux R, Shi W: Inactivation of the ciaH gene in Streptococcus mutans diminishes mutacin production and competence development, alters sucrose-dependent biofilm formation, and reduces stress tolerance. Infect Immun 2004, 72: 4895-4899. (Pubitemid 38989355)
54. Richards JJ, Reed CS, Melander C: Effects of N-pyrrole substitution on the anti-biofilm activities of oroidin derivatives against Acinetobacter baumannii. Bioorg Med Chem Lett 2008, 18: 4325-4327.
55. Huigens RW III, Rogers SA, Steinhauer AT, Melander C: Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 2009, 7: 794-802.
56. Bunders CA, Richards JJ, Melander C: Identification of aryl 2- aminoimidazoles as biofilm inhibitors in Gram-negative bacteria. Bioorg Med Chem Lett 2010, 20: 3797-3800.
57. Peng L, Desousa J, Su Z et al.: Inhibition of Acinetobacter baumannii biofilm formation on a methacrylate polymer containing a 2-aminoimidazole subunit. Chem Commun (Camb) 2011, 47: 4896-4898.
58. Stowe SD, Richards JJ, Tucker AT, Thompson R, Melander C, Cavanagh J: Anti-biofilm compounds derived from marine sponges. Mar Drugs 2011, 9: 2010-2035.
59. Yeagley AA, Su Z, Mccullough KD, Worthington RJ, Melander C: N-substituted 2-aminoimidazole inhibitors of MRSA biofilm formation accessed through direct 1,3-bis(tert-butoxycarbonyl)guanidine cyclization. Org Biomol Chem 2013, 11:130-137
60. Ballard TE, Richards JJ, Wolfe AL, Melander C: Synthesis and antibiofilm activity of a second-generation reverse-amide oroidin library: a structure-activity relationship study. Chem Eur J 2008, 14: 10745-10761.
61. Thompson RJ, Bobay BG, Stowe SD et al.: Identification of BfmR, a response regulator involved in biofilm development, as a target for a 2-aminoimidazole-based antibiofilm agent. Biochemistry 2012, 51: 9776-9778.
62. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J: Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000, 31: 101-106. (Pubitemid 32268946)
63. Flemming HC, Wingender J: The biofilm matrix. Nat Rev Microbiol 2010, 8: 623-633.
64. Mah TF, O'toole GA: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001, 9: 34-39.
65. Kaplan JB: Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res 2010, 89: 205-218.
66. Izano EA, Amarante MA, Kher WB, Kaplan JB: Differential roles of poly-N-acetylglucosamine surface polysaccharide and extracellular DNA in Staphylococcus aureus and Staphylococcus epidermidis biofilms. Appl Environ Microbiol 2008, 74: 470-476.
67. Itoh Y, Wang X, Hinnebusch BJ, Preston JF III, Romeo T: Depolymerization of beta-1,6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. J Bacteriol 2005, 187: 382-387. (Pubitemid 40024214)
68. Kaplan JB, Ragunath C, Velliyagounder K, Fine DH, Ramasubbu N: Enzymatic detachment of Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2004, 48: 2633-2636. (Pubitemid 38823436)
69. Donelli G, Francolini I, Romoli D et al.: Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes. Antimicrob Agents Chemother 2007, 51: 2733-2740. (Pubitemid 47206207)
70. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S: Antimicrobial and antibiofilm efficacy of triclosan and dispersinB combination. J Antimicrob Chemother 2009, 64: 88-93.
71. Alkawash MA, Soothill JS, Schiller NL: Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 2006, 114: 131-138. (Pubitemid 43356924)
72. Alipour M, Suntres ZE, Omri A: Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 2009, 64: 317-325.
73. Bayer AS, Park S, Ramos MC, Nast CC, Eftekhar F, Schiller NL: Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa. Infect Immun 1992, 60: 3979-3985.
74. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS: Extracellular DNA required for bacterial biofilm formation. Science 2002, 295:1487. (Pubitemid 34173996)
75. Tetz VV, Tetz GV: Effect of extracellular DNA destruction by DNase I on characteristics of forming biofilms. DNA Cell Biol 2010, 29: 399-405.
76. Kiedrowski MR, Kavanaugh JS, Malone CL et al.: Nuclease modulates biofilm formation in community-associated methicillin-resistant Staphylococcus aureus. PLoS ONE 2011, 6:e26714.
77. Mann EE, Rice KC, Boles BR et al.: Modulation of eDNA release and degradation affects Staphylococcus aureus biofilm maturation. PLoS ONE 2009, 4:e5822.
78. Kaplan JB, Lovetri K, Cardona ST et al.: Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo) 2012, 65: 73-77.
79. Hall-Stoodley L, Nistico L, Sambanthamoorthy K et al.: Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. BMC Microbiol 2008, 8:173.
80. Parsiegla G, Noguere C, Santell L, Lazarus RA, Bourne Y: The structure of human DNase I bound to magnesium and phosphate ions points to a catalytic mechanism common to members of the DNase I-like superfamily. Biochemistry 2012, 51: 10250-10258.
81. Hoiby N, Ciofu O, Bjarnsholt T: Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010, 5: 1663-1674.
82. Frederiksen B, Pressler T, Hansen A, Koch C, Hoiby N: Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006, 95: 1070-1074. (Pubitemid 44385111)
83. Boles BR, Horswilla R: Agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog 2008, 4:e1000052.
84. Iwase T, Uehara Y, Shinji H et al.: Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 2010, 465: 346-349.
85. Park JH, Lee JH, Cho MH, Herzberg M, Lee J: Acceleration of protease effect on Staphylococcus aureus biofilm dispersal. FEMS Microbiol Lett 2012, 335: 31-38.
86. Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MC: Proteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Chemother 1993, 37: 2618-2621. (Pubitemid 23357856)
87. Longhi C, Scoarughi GL, Poggiali F et al.: Protease treatment affects both invasion ability and biofilm formation in Listeria monocytogenes. Microb Pathog 2008, 45: 45-52.
88. Jackson KD, Starkey M, Kremer S, Parsek MR, Wozniak DJ: Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J Bacteriol 2004, 186: 4466-4475. (Pubitemid 38891009)
89. Digiandomenico A, Warrener P, Hamilton M et al.: Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 2012, 209: 1273-1287.
90. Maira-Litran T, Kropec A, Goldmann DA, Pier GB: Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 2005, 73: 6752-6762. (Pubitemid 41368842)